Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: a case report
© The Author(s) 2017
Received: 13 October 2016
Accepted: 14 December 2016
Published: 4 January 2017
Although data from several studies support the use of arginine vasopressin (AVP) for the treatment of hypotension concomitant with pulmonary hypertension (PH) in the cardiac surgery setting, to our knowledge, no previous studies have reported the effect of AVP on the systemic and pulmonary circulation of patients with PH secondary to lung diseases. In this report, we present the hemodynamic responses to bolus administrations of AVP and noradrenaline in a patient with PH secondary to pulmonary emphysema. The patient showed low systemic vascular resistance hypotension during off-pump single-lung transplantation. The bolus administration of AVP (0.5 U) increased systemic arterial pressure by 35.2%, with a minimal change in pulmonary arterial pressure, resulting in a significant decrease in the pulmonary arterial pressure/systemic arterial pressure ratio. In contrast, the bolus administration of noradrenaline (10 or 20 μg) increased both systemic and pulmonary arterial pressures by 14.8 and 6.7%, respectively. In summary, the bolus administration of AVP effectively increased systemic arterial pressure with a minimal effect on pulmonary arterial pressure in a patient with PH secondary to pulmonary emphysema. This case highlights the potential utility of AVP to treat low systemic vascular resistance hypotension in patients with PH secondary to lung diseases.
KeywordsPulmonary hypertension Hypotension Vasopressor Arginine vasopressin Noradrenaline
Surgery and anesthesia pose a significant risk for patients with pulmonary hypertension (PH) [1–3]; therefore, perioperative management of these patients presents a major challenge to physicians. Several studies in patients undergoing cardiac surgery have demonstrated that arginine vasopressin (AVP) can effectively ameliorate systemic hypotension without increasing pulmonary vascular resistance [4–6]. These results support the administration of AVP for the treatment of hypotension concomitant with PH in the cardiac surgery setting. However, to our knowledge, no previous studies have reported the effect of AVP on the systemic and pulmonary circulation of patients with PH secondary to lung diseases. In this report, we present the hemodynamic responses to bolus administrations of AVP and noradrenaline (NAD) in a patient with PH secondary to pulmonary emphysema. The patient showed low systemic vascular resistance hypotension during off-pump single-lung transplantation. We discuss the challenge of managing intraoperative hypotension in a patient with PH, with focus on the choice of vasopressor in this setting.
A 61-year-old man (174 cm, 56 kg) with pulmonary emphysema and secondary PH underwent off-pump, single-right-lung transplantation from a brain-dead donor. His preoperative status was Hugh–Jones class IV (unable to walk more than about 50 m without rest), and arterial blood gas analysis at admission showed a PaO2 of 74.9 mm Hg and a PaCO2 of 35.3 mm Hg at an inhalation rate of 1 L/min O2. A preoperative transthoracic echocardiogram showed normal left ventricular systolic function (ejection fraction, 60%) and PH with an estimated systolic pulmonary arterial pressure (PAP) of 66 mm Hg. Symptoms of right heart failure, such as lower-limb edema, were not present. Written informed consent was obtained from the patient for the publication of this case report.
The patient exhibited low systemic vascular resistance hypotension (systemic vascular resistance, 280–520 dyne s cm−5; systolic SAP, 70–90 mm Hg) during the surgery. Therefore, continuous infusion of dopamine (2–3 μg/kg/min), NAD (0.1–0.2 μg/kg/min), and AVP (2 U/h) was administered to maintain SAP. In addition, bolus administrations of NAD (10 or 20 μg, administered 15 times) or AVP (0.5 U, administered twice) were used from the time of clamping of the pulmonary artery until initiation of reperfusion. The intervals between bolus administrations of NAD and AVP ranged from 3 to 12 min. The patient’s cardiac index remained high (4.1–7.6 L/min/m2) throughout the operation.
Systolic PAP decreased with reperfusion and remained in the range of 40–50 mm Hg thereafter. Systolic SAP also decreased after reperfusion and several bolus doses of NAD were required, although this stabilized within about 40 min. The transplanted lung had adequate perfusion and oxygenation. The operating time was 358 min and the total volume of blood loss was 613 mL; no blood transfusion was required. The postoperative course was largely uneventful, except for a tracheostomy, which was performed on postoperative day 2, owing to pulmonary edema in the transplanted lung. The patient was weaned from the ventilator on postoperative day 8 and from inotropic support on postoperative day 10. The patient was discharged from the hospital 10 weeks after surgery.
Here, we present a case of off-pump single-lung transplantation for pulmonary emphysema concomitant with secondary PH, in which the bolus administration of AVP effectively increased SAP with a minimal effect on PAP.
Maintaining adequate SAP is especially important in patients with PH, because systemic hypotension decreases coronary perfusion pressure, thereby causing myocardial ischemia and right heart failure [7, 8]. The ideal vasopressor agent for patients with PH should increase systemic vascular resistance with a minimal effect on pulmonary vascular resistance and improve the contractility of the right ventricle; however, most vasopressors used in clinical anesthesia and intensive care for the augmentation of systemic vascular resistance will also increase pulmonary vascular resistance . For example, sympathomimetic vasopressors, such as NAD, exert their systemic vasopressor effects through α1-adrenoceptor agonism, which also causes pulmonary vasoconstriction and may potentially impair right ventricular function . In fact, noradrenaline caused elevation of PAP in our patient, although to a lesser degree than that of SAP.
AVP is a nonsympathomimetic vasopressor, which causes vasoconstriction via activation of the V1 vasopressin receptor . In vitro and in vivo studies have demonstrated that AVP produces systemic vasoconstriction with relatively fewer effects on the pulmonary circulation; such combined effects produce a desirable decrease in the pulmonary vascular resistance/systemic vascular resistance ratio [12–14]. This AVP-mediated selective vasoconstriction of the systemic vessels has also been shown in several clinical studies in patients undergoing cardiac surgery [4–6]. However, the pathological mechanisms of PH in patients who undergo cardiac surgery are different from those in patients with PH secondary to lung diseases. PH in cardiac surgery patients is commonly caused by elevated pulmonary venous pressure, whereas that secondary to lung diseases is caused by alterations in lung structure or function . To date, data on the effect of AVP on systemic and pulmonary circulation in patients with PH secondary to lung diseases are lacking. In our patient, the bolus administration of AVP selectively increased SAP, which seems to reflect selective vasoconstriction of the systemic vessels. This phenomenon suggests that patients with PH secondary to lung diseases also benefit from the administration of AVP for the treatment of systemic hypotension.
The data presented in this report should be interpreted cautiously. Although the authors analyzed the hemodynamic responses to bolus administrations of AVP and NAD, continuous infusion of these drugs might have different effects. In addition, several drugs, including AVP and NAD, that have influence on systemic and pulmonary vascular resistance were continuously administered during the surgery. Although the administration flow rate of these drugs was constant in most of the period from the time of clamping of the pulmonary artery until reperfusion, continuous infusion of these drugs might have affected the observed hemodynamic responses.
Although AVP is not indicated for treatment of hypotension in Japan, AVP was used without the approval of the Ethics Committee in this case because it was an emergent situation in which hypotension persisted despite the administration of NAD and we did not have time to wait for Ethics Committee approval. However, AVP use in vasodilatory shock has been shown to be safe in many studies  and was approved in 2014 by the Food and Drug Administration . We consider that AVP use in this case was not ethically problematic.
The potential risks associated with the administration of AVP should be carefully considered. AVP may cause myocardial dysfunction probably owing to direct myocardial effects, including coronary vasoconstriction . Cardiac function should be closely monitored using a pulmonary artery catheter or transesophageal echocardiography during the administration of AVP.
The authors observed a 35.2% increase in SAP with a minimal change in PAP, resulting in a significant decrease in the PAP/SAP ratio after the bolus administration of AVP in a patient with PH secondary to pulmonary emphysema. This case highlights the potential utility of AVP to treat low systemic vascular resistance hypotension in patients with PH secondary to lung diseases.
Pulmonary arterial pressure
Systemic arterial pressure
The authors would like to thank Enago (www.enago.jp) for the English language review.
TM was involved in patient care during the surgery and prepared the manuscript. KF, MH, and SM helped draft the manuscript. HS critically revised the manuscript. All authors read and approved the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for the publication of this report.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Lai HC, Lai HC, Wang KY, Lee WL, Ting CT, Liu TJ. Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth. 2007;99:184–90.View ArticlePubMedGoogle Scholar
- Price LC, Montani D, Jaïs X, Dick JR, Simonneau G, Sitbon O, Mercier FJ, Humbert M. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J. 2010;35:1294–302.View ArticlePubMedGoogle Scholar
- Kaw R, Pasupuleti V, Deshpande A, Hamieh T, Walker E, Minai OA. Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery. Respir Med. 2011;105:619–24.View ArticlePubMedGoogle Scholar
- Jeon Y, Ryu JH, Lim YJ, Kim CS, Bahk JH, Yoon SZ, Choi JY. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg. 2006;29:952–6.View ArticlePubMedGoogle Scholar
- Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2007;6:715–9.View ArticlePubMedGoogle Scholar
- Yimin H, Xiaoyu L, Yuping H, Weiyan L, Ning L. The effect of vasopressin on the hemodynamics in CABG patients. J Cardiothorac Surg. 2013;8:49.View ArticlePubMedPubMed CentralGoogle Scholar
- Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology. 2003;99:1415–32.View ArticlePubMedGoogle Scholar
- Pritts CD, Pearl RG. Anesthesia for patients with pulmonary hypertension. Curr Opin Anaesthesiol. 2010;23:411–6.View ArticlePubMedGoogle Scholar
- Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev. 1995;47:87–131.PubMedGoogle Scholar
- Bergofsky EH. Humoral control of the pulmonary circulation. Annu Rev Physiol. 1980;42:221–33.View ArticlePubMedGoogle Scholar
- Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med. 2007;35:33–40.View ArticlePubMedGoogle Scholar
- Walker BR, Haynes Jr J, Wang HL, Voelkel NF. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol. 1989;257:H415–22.PubMedGoogle Scholar
- Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries. Anesthesiology. 2014;121:930–6.View ArticlePubMedGoogle Scholar
- Sarkar J, Golden PJ, Kajiura LN, Murata LA, Uyehara CF. Vasopressin decreases pulmonary-to-systemic vascular resistance ratio in a porcine model of severe hemorrhagic shock. Shock. 2015;43:475–82.View ArticlePubMedGoogle Scholar
- Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.View ArticlePubMedGoogle Scholar
- Serpa Neto A, Nassar AP, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, Damasceno MC, Russell JA. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012;16:R154.View ArticlePubMedPubMed CentralGoogle Scholar
- U. S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed 5 Dec 2016.
- Boyle 3rd WA, Segel LD. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol. 1986;251:H734–41.PubMedGoogle Scholar